title: [Spontaneous and treatment-induced virological dynamic in the plasma, PBMC and liver tissue in a patient with chronic HBV and HCV coinfection].
abstract: Here it is reported the virological dynamic of HBV and HCV, identified in the plasma, peripheral blood mononuclear cells and tissue liver, in a patient with chronic HBV-HCV coinfection. A treatment with pegylated Interferon plus Ribavirin determined a sustained virological response for HCV in all the three studied compartments, but a reactivation of chronic HBV infection was observed. In fact, while at the first observation HBV-DNA was detectable only in the liver tissue, after antiviral therapy it was detectable in all the three compartments; moreover this HBV reactivation was associated with a hepatic flare. Then, the patient was treated with Entecavir, which has been determining the clearance of HBV from the peripheral compartments (plasma and PBMC) until today.
authors: Dipartimento di Medicina Pubblica, Clinica e Preventiva, Seconda Universita di Napoli, Divisione di Malattie Infettive, Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta, Italy.
authors: Maria
authors: M
authors: Stanzione
authors: Gilda
authors: G
authors: Tonsiello
authors: Valentina
authors: V
authors: Iodice
authors: Margherita
authors: M
authors: Macera
authors: Evangelista
authors: E
authors: Sagnelli
authors: Felice
authors: F
authors: Piccinino
authors: Nicola
authors: N
authors: Coppola
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006510:Hepatitis B Antibodies / Q000097:blood; D006511:Hepatitis B Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000821:virology*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000821:virology; D008099:Liver / Q000473:pathology / Q000821:virology; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology / Q000821:virology; D008297:Male; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000821:virology*
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D018937:Hepatitis C Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin